By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen-Cilag International NV 

1, rue Camille Desmoulins
TSA 91003
Issy-les-Moulineaux  Cedex  92787  France
Phone: 33-1-5500-4500 Fax: 33-1-5500-2885



Company News
Janssen-Cilag International NV (JNJ) Presents New Data Assessing OLYSIO (Simeprevir) In Combination With Sofosbuvir In Genotype 4 Infected HCV Patients In Egypt 11/16/2015 11:48:30 AM
Janssen-Cilag International NV (JNJ) Submits Application To The European Medicines Agency To Expand Use Of IMBRUVICA® (Ibrutinib) In Previously Untreated Chronic Lymphocytic Leukaemia Patients 11/3/2015 11:01:56 AM
Janssen-Cilag International NV (JNJ) Receives Positive CHMP Opinion Recommending EDURANT (rilpivirine) For The Treatment Of Adolescents Aged 12 To <18 Years With HIV-1 Infection 10/26/2015 9:19:07 AM
Janssen-Cilag International NV (JNJ) Release: First Data From Europe’s First And Largest Prospective Observational Study Of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presented At The 2015 European Cancer Congress (ECC2015) 9/29/2015 12:22:16 PM
Janssen-Cilag International NV (JNJ)’s Daratumumab Accepted For Accelerated CHMP Assessment For Treatment Of European Patients With Heavily Pre-Treated Multiple Myeloma 9/25/2015 10:47:01 AM
Janssen-Cilag International NV (JNJ) Submits European Extension Marketing Authorisation Application For Paliperidone Palmitate Once-Every-Three-Months Formulation 8/21/2015 9:29:19 AM
Janssen-Cilag International NV (JNJ) Release: STELARA Receives CHMP Positive Opinion For Treatment Of Adolescents With Moderate To Severe Psoriasis In Europe 5/22/2015 6:28:47 AM
European Commission (EC) Approves Janssen-Cilag International NV (JNJ)'s Rezolsta 11/25/2014 5:48:11 AM
Janssen-Cilag International NV (JNJ) Release: CHMP Announces Positive Opinion For REZOLSTA™, A New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir And Cobicistat 9/29/2014 8:49:54 AM
Janssen-Cilag International NV (JNJ) Release: Analysis Of Pooled Data From Phase 3 Trial Results Show Glycaemic Efficacy Of INVOKANA® (Canagliflozin) Is Largely Independent Of Beta-Cell Function And Insulin Sensitivity In The Treatment Of Type 2 Diabetes In Adults 9/17/2014 11:23:27 AM